This inventor holds 32 USPTO granted patents and 17 published patent applications, plus 11 CIPO patents and 22 EPO patents, primarily in Cancer Treatment. Top assignees: Apeiron Biologics Ag, Attoquant Diagnostics Gmbh, Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag. Active years: 1985-2023.
Company Filing History:
13 out of 15 
3 out of 5 
3 out of 3 
Years Active: 1985-2023
Areas of Expertise:
Title: The Innovative Contributions of Hans Loibner in Cancer Treatment
Introduction
Hans Loibner, an accomplished inventor based in Vienna, Austria, has made significant strides in the field of cancer treatment through his remarkable innovations. With a portfolio of 32 patents to his name, Loibner's work focuses on developing novel therapies aimed at combating GD2 positive cancers, particularly high-risk neuroblastoma.
Latest Patents
One of Loibner's most notable inventions involves preparations and methods for treating GD2 positive cancer by administering a chimeric or humanized anti-GD2 antibody to patients. This method emphasizes the administration of the antibody without concomitant treatment with Interleukin-2 (IL-2). Additionally, his research highlights continuous infusion strategies of anti-GD2 antibodies and explores the involvement of retinoid treatments during various stages of therapy.
Career Highlights
His career has seen significant affiliations with leading firms like Apeiron Biologics AG and Sandoz GmbH. These roles have allowed him to push the boundaries of cancer treatment, contribute to the development of pioneering therapies, and actively participate in clinical advancements within the biotechnology field.
Collaborations
Throughout his journey, Hans Loibner has collaborated with esteemed colleagues, including Manfred Schuster and Oliver Mutschlechner. These partnerships have played a crucial role in enhancing his research and expanding the impact of his innovative approaches to cancer therapy.
Conclusion
Hans Loibner's commitment to advancing cancer treatment through innovative inventions underscores the vital role of inventors in medicine. His work not only highlights the significance of targeted therapies but also reflects a dedication to improving patient outcomes. With numerous patents and collaborations to his credit, Loibner continues to be a pivotal figure in the medical research landscape.